KR20150119227A - 라퀴니모드에 의한 다발성 경화증의 진행형 형태의 치료 - Google Patents

라퀴니모드에 의한 다발성 경화증의 진행형 형태의 치료 Download PDF

Info

Publication number
KR20150119227A
KR20150119227A KR1020157024953A KR20157024953A KR20150119227A KR 20150119227 A KR20150119227 A KR 20150119227A KR 1020157024953 A KR1020157024953 A KR 1020157024953A KR 20157024953 A KR20157024953 A KR 20157024953A KR 20150119227 A KR20150119227 A KR 20150119227A
Authority
KR
South Korea
Prior art keywords
mode
subject
multiple sclerosis
progressive
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020157024953A
Other languages
English (en)
Korean (ko)
Inventor
노라 타르식
단 바르-조하르
리아트 하야르데니
요시 길건 쉐르키
탈리 고르핀
볼커 크나퍼츠
엘라 소라니
Original Assignee
테바 파마슈티컬 인더스트리즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51351655&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20150119227(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 테바 파마슈티컬 인더스트리즈 리미티드 filed Critical 테바 파마슈티컬 인더스트리즈 리미티드
Publication of KR20150119227A publication Critical patent/KR20150119227A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
KR1020157024953A 2013-02-15 2014-02-13 라퀴니모드에 의한 다발성 경화증의 진행형 형태의 치료 Withdrawn KR20150119227A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361765394P 2013-02-15 2013-02-15
US61/765,394 2013-02-15
US201361911106P 2013-12-03 2013-12-03
US61/911,106 2013-12-03
PCT/US2014/016278 WO2014127139A1 (en) 2013-02-15 2014-02-13 Treatment of multiple sclerosis with laquinimod

Publications (1)

Publication Number Publication Date
KR20150119227A true KR20150119227A (ko) 2015-10-23

Family

ID=51351655

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157024953A Withdrawn KR20150119227A (ko) 2013-02-15 2014-02-13 라퀴니모드에 의한 다발성 경화증의 진행형 형태의 치료

Country Status (18)

Country Link
US (2) US20140235670A1 (cg-RX-API-DMAC10.html)
EP (1) EP2956137A4 (cg-RX-API-DMAC10.html)
JP (1) JP2016510343A (cg-RX-API-DMAC10.html)
KR (1) KR20150119227A (cg-RX-API-DMAC10.html)
CN (1) CN105163737A (cg-RX-API-DMAC10.html)
AU (1) AU2014216199A1 (cg-RX-API-DMAC10.html)
BR (1) BR112015019564A2 (cg-RX-API-DMAC10.html)
CA (1) CA2900503A1 (cg-RX-API-DMAC10.html)
CL (1) CL2015002181A1 (cg-RX-API-DMAC10.html)
EA (1) EA201591507A1 (cg-RX-API-DMAC10.html)
HK (2) HK1218254A1 (cg-RX-API-DMAC10.html)
IL (1) IL240014A0 (cg-RX-API-DMAC10.html)
MX (1) MX2015010296A (cg-RX-API-DMAC10.html)
PE (1) PE20151526A1 (cg-RX-API-DMAC10.html)
SG (1) SG11201505818WA (cg-RX-API-DMAC10.html)
TW (1) TW201442709A (cg-RX-API-DMAC10.html)
UY (1) UY35328A (cg-RX-API-DMAC10.html)
WO (1) WO2014127139A1 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013116657A1 (en) 2012-02-03 2013-08-08 Teva Pharmaceutical Industries Ltd. USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY
TW201804997A (zh) * 2012-05-02 2018-02-16 以色列商泰瓦藥品工業有限公司 高劑量拉喹莫德(laquinimod)於治療多發性硬化症之用途
HK1231413A1 (zh) 2014-04-29 2017-12-22 Teva Pharmaceutical Industries Ltd. 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德
CA2964315A1 (en) * 2014-10-16 2016-04-21 Novartis Ag Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis
US10091217B2 (en) 2016-06-21 2018-10-02 Logrhythm, Inc. Risk based priority processing of data
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
AU2017319728B2 (en) 2016-08-31 2024-09-05 Mapi Pharma Ltd Depot systems comprising glatiramer acetate
IL316573A (en) * 2017-03-26 2024-12-01 Mapi Pharma Ltd Storage systems containing glatiramer acetate for the treatment of multiple sclerosis
WO2022011155A1 (en) * 2020-07-09 2022-01-13 Oklahoma Medical Research Foundation Biomarkers for identifying relapses in multiple sclerosis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
CN101466379B (zh) * 2006-06-12 2012-10-31 泰华制药工业有限公司 稳定的拉喹莫德的制剂
CA2693697C (en) * 2007-07-11 2017-07-25 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
AR073295A1 (es) * 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
EP2375900B1 (en) * 2008-12-11 2016-03-02 Biovista, Inc. Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles
NZ597378A (en) * 2009-06-19 2014-08-29 Teva Pharma Treatment of multiple sclerosis with laquinimod
PE20140872A1 (es) * 2010-12-07 2014-08-09 Teva Pharma Uso de laquinimod para reducir la fatiga, mejorar el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple
HK1198278A1 (en) * 2011-07-28 2015-03-27 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and interferon-beta
TW201804997A (zh) * 2012-05-02 2018-02-16 以色列商泰瓦藥品工業有限公司 高劑量拉喹莫德(laquinimod)於治療多發性硬化症之用途
MX2015004564A (es) * 2012-10-12 2015-07-21 Teva Pharma Laquinimod para producir el daño talamico en la esclerosis multiple.
HK1231413A1 (zh) * 2014-04-29 2017-12-22 Teva Pharmaceutical Industries Ltd. 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德

Also Published As

Publication number Publication date
MX2015010296A (es) 2016-05-05
HK1218254A1 (zh) 2017-02-10
HK1218251A1 (zh) 2017-02-10
TW201442709A (zh) 2014-11-16
US20140235670A1 (en) 2014-08-21
EP2956137A1 (en) 2015-12-23
IL240014A0 (en) 2015-09-24
BR112015019564A2 (pt) 2017-07-18
US20180064702A1 (en) 2018-03-08
WO2014127139A1 (en) 2014-08-21
EA201591507A1 (ru) 2015-12-30
AU2014216199A1 (en) 2015-09-03
PE20151526A1 (es) 2015-11-20
JP2016510343A (ja) 2016-04-07
CA2900503A1 (en) 2014-08-21
UY35328A (es) 2014-09-30
CL2015002181A1 (es) 2016-06-03
EP2956137A4 (en) 2016-08-03
CN105163737A (zh) 2015-12-16
SG11201505818WA (en) 2015-08-28

Similar Documents

Publication Publication Date Title
US20180064702A1 (en) Treatment of progressive forms of multiple sclerosis with laquinimod
JP2017061482A (ja) ラキニモドおよびインターフェロンβを組み合わせた多発性硬化症の治療
JP2017081930A (ja) ラキニモドおよび酢酸グラチラマーを組み合わせた多発性硬化症の治療
KR20150003765A (ko) 라퀴니모드와 디메틸 푸마레이트의 병용물에 의한 다발성 경화증의 치료
JP2017222691A (ja) 多発性硬化症を治療するための高投与量ラキニモドの使用
KR20170109091A (ko) 라퀴니모드를 이용한 다발경화증의 치료
US20160296511A1 (en) Laquinimod for reducing thalamic damage in multiple sclerosis
US20160235735A1 (en) Treatment of multiple sclerosis with combination of laquinimod and fampridine
JP2017514824A (ja) 能力障害度が高い再発寛解型多発性硬化症（ｒｒｍｓ）患者の処置のためのラキニモド
WO2025068949A1 (en) Emrusolmin for use in treating multiple system atrophy
TW201404394A (zh) 以拉喹莫德（ＬＡＱＵＩＮＩＭＯＤ）及β－干擾素之組合治療多發性硬化症
TW201404395A (zh) 以拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）及醋酸格拉替雷（ｇｌａｔｉｒａｍｅｒ ａｃｅｔａｔｅ）之組合治療多發性硬化症

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid
R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000